You have 9 free searches left this month | for more free features.

Lenalidomide

Showing 26 - 50 of 1,173

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Primary CNS Lymphoma Trial in Hangzhou (Rituximab, Lenalidomide, Methotrexate)

Completed
  • Primary Central Nervous System Lymphoma
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Nov 18, 2022

Multiple Myeloma Trial in Boston, Columbus (drug, biological, other)

Terminated
  • Multiple Myeloma
  • lenalidomide
  • +3 more
  • Boston, Massachusetts
  • +1 more
Nov 14, 2022

Multiple Myeloma Trial in Hangzhou (Ixazomib plus low-dose lenalidomide, Ixazomib)

Recruiting
  • Multiple Myeloma
  • Ixazomib plus low-dose lenalidomide
  • Ixazomib
  • Hangzhou, Zhejiang, China
    Yang Xu
Feb 9, 2023

Dermatomyositis Trial in Nanchang (Lenalidomide)

Not yet recruiting
  • Dermatomyositis
  • Lenalidomide
  • Nanchang, Jiangxi, China
    Department of Rheumatology and Clinical Immunology, Jiangxi Prov
Aug 3, 2022

Alkylating Agent-Related Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia Trial in Houston (Laboratory Biomarker

Completed
  • Alkylating Agent-Related Acute Myeloid Leukemia
  • Secondary Acute Myeloid Leukemia
  • Laboratory Biomarker Analysis
  • Lenalidomide
  • Houston, Texas
    M D Anderson Cancer Center
Oct 18, 2022

Lymphoid Leukemia, Small Lymphocytic Lymphoma, Lymphoma, Non-Hodgkin Trial in Madison (Bendamustine, Rituximab, Lenalidomide)

Completed
  • Lymphoid Leukemia
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin
Jan 30, 2023

Primary CNS Lymphoma and Primary Vitreoretinal Lymphoma Trial (intensity-modulated radiotherapy (IMRT))

Not yet recruiting
  • Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma
  • intensity-modulated radiotherapy (IMRT)
  • (no location specified)
Jun 4, 2023

Newly Diagnosed Multiple Myeloma Trial in New York (Daratumumab, Bortezomib, Lenalidomide)

Recruiting
  • Newly Diagnosed Multiple Myeloma
  • New York, New York
    Icahn School of Medicine at Mount Sinai
Dec 29, 2022

DLBCL Trial in San Juan (PF-07901801, Tafasitamab, Lenalidomide)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • San Juan, Puerto Rico
    Auxilio Mutuo Cancer Center
Jan 19, 2023

Multiple Myeloma Trial in Torino (Melphalan, Prednisone, Lenalidomide, Cyclophosphamide, Prednisone, Lenalidomide, Lenalidomide,

Active, not recruiting
  • Multiple Myeloma
  • Melphalan, Prednisone, Lenalidomide
  • +2 more
  • Torino, TO, Italy
    Division Of Hematology, A.O.U. Città della Salute e della Scienz
Mar 24, 2022

Langerhans Cell Histiocytosis (LCH), Histiocytoses Erdheim-chester Disease, Histiocytic Sarcoma (HS) Trial in Boston

Active, not recruiting
  • Langerhans Cell Histiocytosis (LCH)
  • +2 more
  • Lenalidomide
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Aug 26, 2022

Leukemia, Lymphoma Trial in Houston (Rituximab, Lenalidomide)

Active, not recruiting
  • Leukemia
  • Lymphoma
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Oct 11, 2022

Multiple Myeloma Trial in United States (Ixazomib, Lenalidomide, Dexamethasone)

Active, not recruiting
  • Multiple Myeloma
  • Ixazomib
  • +2 more
  • Duarte, California
  • +9 more
Jan 11, 2023

DLBCL Trial in Hangzhou (Tafasitamab and Lenalidomide)

Recruiting
  • DLBCL
  • Tafasitamab and Lenalidomide
  • Hangzhou, Zhejiang, China
    The First Afflicated Hospital, College of Medicine, Zhejiang Uni
Sep 21, 2022

Follicular Lymphoma Trial in Shanghai (lenalidomide, rituximab, parsaclisib)

Not yet recruiting
  • Follicular Lymphoma
  • lenalidomide
  • +2 more
  • Shanghai, Shanghai, China
    Ruijin hospital, school of medicine, Shanghai jiao tong universi
May 10, 2023

Multiple Myeloma Trial in Nantong (Colchicine, Lenalidomide)

Recruiting
  • Multiple Myeloma
  • Nantong, Jiangsu, China
    Affiliated Hospital of Nantong University
Mar 25, 2023

CNS Lymphoma, Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in San Francisco (Tafasitamab, Lenalidomide)

Recruiting
  • CNS Lymphoma
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Aug 10, 2022

Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma Trial run by the NCI (Romidepsin,

Recruiting
  • Cutaneous T-Cell Lymphoma
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 23, 2023

Multiple Myeloma Trial in Seoul (Lenalidomide maintenance)

Recruiting
  • Multiple Myeloma
  • Lenalidomide maintenance
  • Seoul, Korea, Republic of
    Samsung Medical Center
Aug 10, 2022

Diffuse Large-cell B-cell Lymphoma Trial in Seattle (plamotamab, tafasitamab, lenalidomide)

Recruiting
  • Diffuse Large-cell B-cell Lymphoma
  • plamotamab
  • +2 more
  • Seattle, Washington
    Swedish Cancer Center
May 2, 2022

Mantle Cell Lymphoma Trial in Duarte, Ann Arbor, Columbus (Venetoclax, Lenalidomide, Rituximab)

Active, not recruiting
  • Mantle Cell Lymphoma
  • Duarte, California
  • +2 more
Oct 18, 2022

Waldenström's Macroglobulinemia Trial in Busan (Lenalidomide, Bortezomib, Rituximab, Dexamethasone)

Recruiting
  • Waldenström's Macroglobulinemia
  • Lenalidomide, Bortezomib, Rituximab, Dexamethasone
  • Busan, Sue-gu, Korea, Republic of
    Kosin University Gospel Hospital
Mar 31, 2022

Chidamide in Recurrent and Refractory Diffuse Large b

Enrolling by invitation
  • Diffuse Large B-cell Lymphoma
  • Suzhou, Jiangsu, China
    Second Affiliated Hospital of Soochow University
Jan 9, 2023

Diffuse Large B-cell Lymphoma Trial in Wuhan (Mitoxantrone Hydrochloride Liposome, Rituximab, Lenalidomide)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • Mitoxantrone Hydrochloride Liposome
  • +2 more
  • Wuhan, Hubei, China
    Department of Hematology Tongji Hospital, Tongji Medical College
Oct 7, 2022

Relapsed/Refractory Diffuse Large B Cell Lymphoma Trial in Seoul (Glofitamab, Poseltinib, Lenalidomide)

Recruiting
  • Relapsed/Refractory Diffuse Large B Cell Lymphoma
  • Glofitamab, Poseltinib, Lenalidomide
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Nov 28, 2022